8-Benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic Acid (SD-1008), a Novel Janus Kinase 2 Inhibitor, Increases Chemotherapy Sensitivity in Human Ovarian Cancer Cells

Interleukin 6 and the signal transducer and activator of transcription (STAT) 3 proteins have important roles in cancer cell survival and proliferation. Recent studies demonstrate that abnormal STAT3 activation promotes tumor growth and supports survival of many human cancers, and thus, this protein or the pathway responsible for its activation is a potential target for the new anticancer therapy. STAT3 is a DNA binding transcription factor, and therefore, its function depends on nuclear translocation. To discover inhibitors of the STAT3 pathway, we designed a cell-based screening assay capable of identifying small molecules that inhibit nuclear translocation. Among the 2000-compound National Cancer Institute Diversity set, we identified 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008) as a micromolar inhibitor of interleukin-6 or oncostatin-induced STAT3 nuclear translocation. In addition, SD-1008 inhibits tyrosyl phosphorylation of STAT3, Janus kinase 2 (JAK2), and Src. SD-1008 also reduces STAT3-dependent luciferase activity. Biochemical studies with recombinant JAK2 proteins demonstrate that high concentrations of SD-1008 directly inhibit JAK2 kinase autophosphorylation. Exposure of various cell lines to SD-1008 decreases levels of the STAT3-dependent proteins, Bcl-XL and survivin, inducing apoptosis. SD-1008 also enhances apoptosis induced by paclitaxel in ovarian cancer cells. These results demonstrate that SD-1008 directly blocks the JAK-STAT3 signaling pathway in human cancer cells that express constitutively active Stat and add to the growing literature that identifies this pathway as a viable target for drug development. Finally, SD-1008 may be a suitable prototype for further chemical modification and exploration as a therapeutic agent.

[1]  C. Joe,et al.  Notch Signal Activates Hypoxia Pathway through HES1-Dependent SRC/Signal Transducers and Activators of Transcription 3 Pathway , 2009, Molecular Cancer Research.

[2]  I. Roninson,et al.  The STAT3 oncogene as a predictive marker of drug resistance. , 2007, Trends in molecular medicine.

[3]  J. Bradner,et al.  SD-1029 Inhibits Signal Transducer and Activator of Transcription 3 Nuclear Translocation , 2006, Clinical Cancer Research.

[4]  Bianca Sperl,et al.  Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. , 2006, Chemistry & biology.

[5]  J. Bromberg,et al.  Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. , 2006, Cancer research.

[6]  Zhenfeng Duan,et al.  Signal Transducers and Activators of Transcription 3 Pathway Activation in Drug-Resistant Ovarian Cancer , 2006, Clinical Cancer Research.

[7]  S. Eschrich,et al.  Persistent Activation of Stat3 Signaling Induces Survivin Gene Expression and Confers Resistance to Apoptosis in Human Breast Cancer Cells , 2006, Clinical Cancer Research.

[8]  Alan Cantor,et al.  Activation of Stat3 in Primary Tumors from High-Risk Breast Cancer Patients Is Associated with Elevated Levels of Activated Src and Survivin Expression , 2006, Clinical Cancer Research.

[9]  I. Fidler,et al.  Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. , 2005, Cancer research.

[10]  M. Loh,et al.  The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. , 2005, Blood.

[11]  Christopher C Taylor,et al.  SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells. , 2005, Cancer research.

[12]  I. Roninson,et al.  Src inhibits adriamycin-induced senescence and G2 checkpoint arrest by blocking the induction of p21waf1. , 2005, Cancer research.

[13]  J. Turkson,et al.  A Novel Platinum Compound Inhibits Constitutive Stat3 Signaling and Induces Cell Cycle Arrest and Apoptosis of Malignant Cells* , 2005, Journal of Biological Chemistry.

[14]  S. Bellone,et al.  High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. , 2005, Gynecologic oncology.

[15]  D. Gilliland,et al.  The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. , 2005, Mayo Clinic proceedings.

[16]  S. Ramaswamy,et al.  Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. , 2005, Cancer research.

[17]  Kevin M. McBride,et al.  STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[19]  Z. Estrov,et al.  WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML). , 2005, Anticancer research.

[20]  J. Turkson,et al.  Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[22]  Renxiao Wang,et al.  A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[23]  E. Shimizu,et al.  Overexpression of constitutive signal transducer and activator of transcription 3 mRNA in cisplatin-resistant human non-small cell lung cancer cells. , 2005, Oncology reports.

[24]  M. Loh,et al.  The JAK 2 V 617 F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia , but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia , 2005 .

[25]  Z. Duan,et al.  Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines , 2005, Cancer Chemotherapy and Pharmacology.

[26]  Wenjun Cheng,et al.  Activated Signal Transducer and Activator of Transcription (STAT) 3 , 2004, Cancer Research.

[27]  H. Young,et al.  Inactivation of Stat3 in tumor cells: releasing a brake on immune responses against cancer? , 2004, Cancer cell.

[28]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[29]  Zhenfeng Duan,et al.  Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. , 2003, Cancer research.

[30]  B. Bonavida,et al.  Inhibition of Constitutive STAT 3 Activity Sensitizes Resistant Non-Hodgkin ’ s Lymphoma and Multiple Myeloma to Chemotherapeutic Drug-mediated Apoptosis 1 , 2003 .

[31]  B. Bonavida,et al.  Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  J. Pow-Sang,et al.  Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. , 2002, Cancer research.

[33]  J. Bromberg.  Stat proteins and oncogenesis. , 2002, The Journal of clinical investigation.

[34]  S. Mok,et al.  Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells. , 2002, Journal of the National Cancer Institute.

[35]  J. Turkson,et al.  STAT proteins: novel molecular targets for cancer drug discovery , 2000, Oncogene.

[36]  Jiayuh Lin,et al.  Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. , 2000, Gynecologic oncology.

[37]  J. Darnell,et al.  The role of STATs in transcriptional control and their impact on cellular function , 2000, Oncogene.

[38]  C. Schindler,et al.  Cytokines and STAT signaling. , 2000, Advances in pharmacology.

[39]  B. Chabner,et al.  Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[41]  J. Darnell,et al.  Stat3 Activation Is Required for Cellular Transformation by v-src , 1998, Molecular and Cellular Biology.

[42]  J. Turkson,et al.  Stat3 Activation by Src Induces Specific Gene Regulation and Is Required for Cell Transformation , 1998, Molecular and Cellular Biology.

[43]  J. Darnell.  STATs and gene regulation. , 1997, Science.

[44]  Y. Tan,et al.  Activation and association of Stat3 with Src in v-Src-transformed cell lines , 1996, Molecular and cellular biology.